Rhabdomyosarcoma: Still Unresolved Questions but New Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 7945
Special Issue Editors
2. Medical Faculty, University of Tübingen, 72076 Tübingen, Germany
Interests: soft tissue sarcoma; pediatric solid tumors; rhabdomyosarcoma; innovative therapies; molecular profiling; molecular classification of pediatric soft tissue sarcoma; liquid biopsy
2. Medical Faculty, University of Tübingen, 72076 Tübingen, Germany
Interests: soft tissue sarcoma; pediatric solid tumors; rhabdomyosarcoma; innovative therapies; molecular profiling; molecular classification of pediatric soft tissue sarcoma; liquid biopsy
Special Issue Information
Dear Colleagues,
Rhabdomyosarcoma (RMS) is a rare mesodermal tumor that can occur at any age but which is mostly diagnosed in children and adolescents. The cure rates for RMS have increased from 25% in the 1970s to 70% in 1990 due to the efforts of cooperative groups on both sides of the Atlantic. This improvement has mainly been achieved in children and adolescents who were eligible for pediatric clinical trials. Young and elderly adults still have poor outcomes. Similarly, no significant progress has been achieved in patients with metastatic disease. Four major RMS histologic subtypes exist: embryonal, alveolar, pleomorphic, and spindle cell RMS. In the majority of alveolar RMS fusion genes, PAX3/7-FOXO1 are detected. However, there is little known regarding phenotypic and biological heterogeneity across the RMS spectrum, especially for fusion-negative RMS. The recent risk grouping system used to adapt the therapy burden is based on clinical features, pathological subtypes, and PAX3/7-FOXO1 fusion status. However, the stratification parameters do not include the full range of the genetic variability of RMS.
The long-term sequelae remain a major problem in survivors. The current trend is to deescalate chemotherapy and radiotherapy treatment, as many trials in the past have failed to show improved outcomes by increasing the dose administered or providing additional drugs. Special consideration must be given to developing better cooperation with medical oncologists, including young adults in pediatric trials, and developing treatment recommendations for adult patients with biologically different RMS, including recommendations for the lifelong surveillance of survivors of RMS.
For this Special Issue, we welcome original and review papers focusing on the understanding of the genomic landscape and underlying biological mechanisms to identify objective biomarkers for the better stratification and monitoring of therapy and the identification of novel therapeutic targets and therapies. We look also for papers on the late effects and quality of life of RMS long-term survivors in the context of reducing the sequelae through the use of optimal-risk adapted local and systemic therapy. Articles providing solutions for developing overarching trials for all ages are also welcome.
We look forward to receiving your contributions.
Prof. Dr. Ewa Koscielniak
Dr. Monika Sparber-Sauer
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rhabdomyosarcoma
- molecular characterization
- late effects
- RMS predisposition
- innovative therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
